Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fingolimod for multiple sclerosis: a review for the specialist nurse.
Preventive healthcare use among males with multiple sclerosis.
Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ
Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis.
Laquinimod CHMP/EMA opinion
Magnetic Resonance Spectroscopy to Assess NeuroInflammation and Neuropathic Pain.
Agreement between physician's recommendation and fitness-to-drive decision in multiple sclerosis.
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes.
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.
Management of multiple sclerosis: An overview.
Structure of the first sphingosine 1-phosphate receptor.
Multiple sclerosis and pain.
The nocebo effect: A clinicians guide.
Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.
[Chronically Ill and Unemployed? A Review on Vocational Status in Multiple Sclerosis].
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
The gut microbiota and its correlations with the central nervous system disorders.
Medication withdrawal in relapsing-remitting multiple sclerosis: why not?
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Effects of the Anti-Multiple Sclerosis Immunomodulator Laquinimod on Anxiety and Depression in Rodent Behavioral Models.
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
Optic Neuritis Probably Induced by Isotretinoin.
Polyunsaturated fatty acids in multiple sclerosis therapy.
Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon Beta treatment.

Pages